DRS. Curry and Charlton reply

New England Journal of Medicine

Volumn 374, Issue 17, 2016, Pages 1688-

  Curry, Michael P ^a   Charlton, Michael ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN; SOFOSBUVIR PLUS VELPATASVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; SOFOSBUVIR;

CHILD PUGH SCORE; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LETTER; LIVER CIRRHOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT WITHDRAWAL; VIRUS RESISTANCE; FEMALE; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MALE;

ANTIVIRAL AGENTS; CARBAMATES; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; SOFOSBUVIR;

EID: 84973410442     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1601160     Document Type: Letter

References (0)